JP2022510683A5 - - Google Patents

Info

Publication number
JP2022510683A5
JP2022510683A5 JP2021531987A JP2021531987A JP2022510683A5 JP 2022510683 A5 JP2022510683 A5 JP 2022510683A5 JP 2021531987 A JP2021531987 A JP 2021531987A JP 2021531987 A JP2021531987 A JP 2021531987A JP 2022510683 A5 JP2022510683 A5 JP 2022510683A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531987A
Other languages
English (en)
Japanese (ja)
Other versions
JP7539378B2 (ja
JP2022510683A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064692 external-priority patent/WO2020118060A1/en
Publication of JP2022510683A publication Critical patent/JP2022510683A/ja
Publication of JP2022510683A5 publication Critical patent/JP2022510683A5/ja
Priority to JP2024077572A priority Critical patent/JP7720948B2/ja
Application granted granted Critical
Publication of JP7539378B2 publication Critical patent/JP7539378B2/ja
Priority to JP2025099700A priority patent/JP2025134803A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531987A 2018-12-05 2019-12-05 神経刺激性ステロイド及びその使用方法 Active JP7539378B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024077572A JP7720948B2 (ja) 2018-12-05 2024-05-10 神経刺激性ステロイド及びその使用方法
JP2025099700A JP2025134803A (ja) 2018-12-05 2025-06-13 神経刺激性ステロイド及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862775470P 2018-12-05 2018-12-05
US62/775,470 2018-12-05
PCT/US2019/064692 WO2020118060A1 (en) 2018-12-05 2019-12-05 Neuroactive steroids and their methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077572A Division JP7720948B2 (ja) 2018-12-05 2024-05-10 神経刺激性ステロイド及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022510683A JP2022510683A (ja) 2022-01-27
JP2022510683A5 true JP2022510683A5 (cg-RX-API-DMAC7.html) 2022-12-01
JP7539378B2 JP7539378B2 (ja) 2024-08-23

Family

ID=69006056

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021531987A Active JP7539378B2 (ja) 2018-12-05 2019-12-05 神経刺激性ステロイド及びその使用方法
JP2024077572A Active JP7720948B2 (ja) 2018-12-05 2024-05-10 神経刺激性ステロイド及びその使用方法
JP2025099700A Pending JP2025134803A (ja) 2018-12-05 2025-06-13 神経刺激性ステロイド及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024077572A Active JP7720948B2 (ja) 2018-12-05 2024-05-10 神経刺激性ステロイド及びその使用方法
JP2025099700A Pending JP2025134803A (ja) 2018-12-05 2025-06-13 神経刺激性ステロイド及びその使用方法

Country Status (14)

Country Link
US (8) US20230322846A9 (cg-RX-API-DMAC7.html)
EP (1) EP3902818A1 (cg-RX-API-DMAC7.html)
JP (3) JP7539378B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250174100A (cg-RX-API-DMAC7.html)
CN (1) CN113383004A (cg-RX-API-DMAC7.html)
AR (1) AR117264A1 (cg-RX-API-DMAC7.html)
AU (3) AU2019392680B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120872A1 (cg-RX-API-DMAC7.html)
IL (3) IL312610B2 (cg-RX-API-DMAC7.html)
MA (1) MA54594A (cg-RX-API-DMAC7.html)
MX (4) MX2021006618A (cg-RX-API-DMAC7.html)
TW (3) TWI874337B (cg-RX-API-DMAC7.html)
WO (1) WO2020118060A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CA3086299A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP7538040B2 (ja) 2018-01-12 2024-08-21 セージ セラピューティクス, インコーポレイテッド CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
TWI848034B (zh) * 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物
JP7670626B2 (ja) * 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法
CA3143545A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
AU2021238346A1 (en) 2020-03-18 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
CN112679571A (zh) * 2020-12-24 2021-04-20 广西壮族自治区中国科学院广西植物研究所 一种罗汉果醇衍生物单体、其制备方法及应用
EP4392432A2 (en) * 2021-08-25 2024-07-03 Sage Therapeutics, Inc. Positive nmda-modulating compounds and methods of use thereof
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
CN120936616A (zh) 2023-03-14 2025-11-11 库里亚西班牙公司 用于制备3α-羟基-3β-烷基类固醇的方法和中间体
WO2024197317A2 (en) * 2023-03-23 2024-09-26 Emory University Neurosteroids and prodrugs thereof
CN119529013B (zh) * 2024-11-25 2025-11-07 湖南新合新生物医药有限公司 一种祖拉诺龙中间体的合成方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) * 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4060295A (en) 1976-03-15 1977-11-29 Molex Incorporated Zero insertion force printed circuit board edge connector assembly
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
FR2967914A1 (fr) 2010-11-29 2012-06-01 Centre Nat Rech Scient Composes inhibiteurs d'interactions proteine-proteine ciblant les proteines kinases et leurs applications biologiques
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US9725481B2 (en) * 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
WO2017049044A1 (en) 2015-09-16 2017-03-23 Bartolucci Giampiero Ursodeoxycholic acid and brain disorders
WO2017187343A2 (en) 2016-04-29 2017-11-02 Thome Kreutz Fernando Nanoemulsions and methods for cancer therapy
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
EP3728285B1 (en) 2017-12-22 2026-04-08 Sage Therapeutics, LLC Compositions and methods for treating cns disorders
US20200384003A1 (en) 2017-12-29 2020-12-10 Shanghai Lanmu Chemicals Co., Ltd. Triterpenoid-containing pharmaceutical composition and use thereof
US12139508B2 (en) 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
JP2022501348A (ja) 2018-09-19 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. ステロール類似体及びその使用
TWI848034B (zh) 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物
WO2020210117A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
WO2020210116A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
US20220226350A1 (en) 2019-05-30 2022-07-21 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
CA3143545A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
US20220396597A1 (en) 2019-10-25 2022-12-15 Washington University Nmdar inhibiting agents and gabaar potentiating agents and uses thereof
CN115768781A (zh) 2020-06-24 2023-03-07 萨奇治疗股份有限公司 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物

Similar Documents

Publication Publication Date Title
JP2022504607A5 (cg-RX-API-DMAC7.html)
JP2021510695A5 (cg-RX-API-DMAC7.html)
JP2023537632A5 (cg-RX-API-DMAC7.html)
JP2023531517A5 (cg-RX-API-DMAC7.html)
JP2022514385A5 (cg-RX-API-DMAC7.html)
JP2022538301A5 (cg-RX-API-DMAC7.html)
RU2506263C2 (ru) Производные оксазолидиновых антибиотиков
JP2018505898A5 (cg-RX-API-DMAC7.html)
JP2018502891A5 (cg-RX-API-DMAC7.html)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
JP2022538774A5 (cg-RX-API-DMAC7.html)
RU2015126015A (ru) Новые улавливатели в лечении макулодистрофии
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2012526728A5 (cg-RX-API-DMAC7.html)
JP2022538299A5 (cg-RX-API-DMAC7.html)
JP2014514286A5 (cg-RX-API-DMAC7.html)
JPWO2020017587A5 (cg-RX-API-DMAC7.html)
RU2017116197A (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера
JP2017533968A5 (cg-RX-API-DMAC7.html)
CA2737999A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
RU2013154117A (ru) Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы
JP2015536974A5 (cg-RX-API-DMAC7.html)
RU2015121043A (ru) Производные фенилэтилпиридина в качестве ингибиторов PDE-4
JP2013535460A5 (cg-RX-API-DMAC7.html)